Reading EDIT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track EDIT free→Reading EDIT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track EDIT free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and earnings quality cannot be assessed as the company was unprofitable over the past year. Management's recent track record has been fairly steady, but the capital stance is capital unfriendly, indicating less favorable shareholder actions. Risk is high, and the sector backdrop presents a headwind, which may affect overall performance. Peer multiples imply a price about 74% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples while recent financials are weak. If EDIT cuts guidance on the next call, that could be a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $2.46. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $2.46 EDIT trades at 4× p/s, below its 9× p/s peer median. Our $7.74 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 68% below a flat-multiple fair value, below our forecast of about 47%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 1.29x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
5 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.21 → $-0.28 (-30.6% / 30d). 1 raised, 1 cut, 8 covering analysts.
0 upgrades, 0 downgrades / 30d. 54% of analysts rate Buy.
0 positive, 2 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$339.
How much price usually moves either way.
On a bad day, this stock has moved -$889.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,988.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: A big change in management score could mean a better company direction or plan.
Confirms:Management score increases by more than 5 points in the next earnings call on August 11, 2026.
Disproves:Management score decreases or remains flat in the next earnings call.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for EDIT yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Entry into a Material Definitive Agreement. Public Offering On May 26, 2026, Editas Medicine, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC as representatives of the underwriters named therein (the “Underwriters”), relating to an underwritten public offering of 55,555,556 shares (the “Underwritten Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), an…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
EDIT Editas Medicine, Inc. | Typical Show detailsSector percentile: 31 of 100 | inexpensive | high |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Editas aims to start a first-in-human study with early proof-of-concept data by the end of 2026.
Stated in 2 of last 2 quarters. The company has reiterated its commitment to initiate a first-in-human study by the end of 2026. However, financials show a decline in revenue from $24.74M in 2025-Q4 to $2.83M in 2026-Q1, indicating limited progress in financial terms. Persistent statement, limited substantive delivery this quarter.
“We remain on track to initiate a first-in-human study with early human proof-of-concept data by the end of 2026.”
“We remain on track to initiate a first-in-human study with early human proof-of-concept data by the end of 2026.”
Editas expects existing cash and cash equivalents to fund operations into the third quarter of 2027.
Newly stated in 2025-Q4. The company expects to fund operations into Q3 2027 with existing cash. However, cash from operating activities was negative at -$23.06M in 2026-Q1, indicating financial strain. Recurring focus, narrow delivery so far.
“The Company expects that the existing cash and cash equivalents will enable the Company to fund its operating expenses and capital expenditure requirements into the third quarter of 2027.”
Why it matters: If companies like Lilly or Johnson & Johnson do well, it may change how people see Editas.
Confirms one read:Lilly or Johnson & Johnson report strong earnings growth above 15% in their next earnings.
Confirms the other:Lilly or Johnson & Johnson report earnings growth below 5% in their next earnings.
Why it matters: If healthcare sector growth speeds up, it may help Editas perform better.
Confirms:Healthcare sector revenue growth speeds up above 10% each year.
Disproves:Healthcare sector revenue growth slows down below 5% each year.
Other Events. The full text of the press release announcing the pricing of the underwritten public offering on May 26, 2026 is attached as Exhibit 99.1 hereto and is incorporated herein by reference. Cash Runway Based upon the Company’s current plans and forecasted expenses, the Company estimates that the net proceeds from the underwritten offering, together with the Company’s cash and cash equivalents as of March 31, 2026, will enable the Company to fund its operations into the second half o…
Other Events. On May 26, 2026, Editas Medicine, Inc. (the “Company”) notified TD Securities (USA) LLC (“TD Cowen”) that it was suspending and terminating the prospectus supplement, dated March 21, 2025, related to the sales agreement that the Company entered into with TD Cowen on May 14, 2021, as amended on February 28, 2024 and on March 5, 2025 (as amended, the “Sales Agreement”), and pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share (th…
Other Events. On May 25, 2026, the Company announced in an oral presentation at the 94 th European Atherosclerosis Society (EAS) Congress new preclinical data for EDIT-401, its lead in vivo development candidate, from preclinical studies in non-human primates (“NHPs”). In the data presented, EDIT-401 achieved robust reductions in LDL-cholesterol (“LDL-C”), lipoprotein(a) (“Lp(a)”), and apolipoprotein B (“ApoB”). The findings presented included: · A single dose of EDIT-401 achieved a 90% or gr…
in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.